InvestorsHub Logo
Followers 40
Posts 3318
Boards Moderated 0
Alias Born 08/18/2009

Re: tykundegex post# 1

Wednesday, 10/31/2018 12:56:26 PM

Wednesday, October 31, 2018 12:56:26 PM

Post# of 4
Stock price down 75% since that post.. and the company has advanced considerably on both their Reservatrol and Stevia programs. With their Cargill JV, Eversweet should start to see sales ramp this Q and in 2019. With Reservatrol, very encouraging findings from the prelim results of a 2 year study (see below) and with Nootkatone a potential deal with the US CDC (and with EPA approval imminent?!).

Reservatrol Study results at 1 year:

"Preliminary results provided from an interim evaluation after 12 months (halfway) in the trial revealed significant benefits of RES vs placebo. Headline results included that RES reduced the loss of bone mineral density in the neck of the femur resulting in a 12% improvement in the FRAX t-score, a 36% reduction in hip fracture risk and a 9% reduction in the 10 year risk of a major osteoporotic fracture."

The core tech of this company is to synthesize natural compounds in yeast, but on an industrial scale, producing exact replicas of the natural compounds but with lower cost and higher purity. From what I can tell, their yeast-based process is one of the most advanced in the world, and has some decent IP to protect it.

Applications today cover reservatrol, nootkatone, stevia extracts, vanillin, and valencene, but the approach would seem to be applicable to many many other natural compounds (I'm thinking canabinoids).

I am taking a long position in Evola this week.